Back to today’s briefing

Story perspectives

CityUHK's Genome Editing Project Targets Liver, Heart Diseases

10/1/2025

50 6 Full Breakdown

Summary

Story summary

City University of Hong Kong (CityUHK) leads a government-funded genome editing project to treat liver and cardiovascular genetic diseases.
The plan aims for one-and-done therapies via DNA surgery over three years.
Led by Professor Zheng Zongli, the team uses engineered lipid nanoparticles (eLNPs) for delivery.
Drug candidates PL-100 and PL-200 target liver diseases and cardiovascular issues, emphasizing safety and efficacy.

1 of 1

Story summary

City University of Hong Kong (CityUHK) leads a government-funded genome editing project to treat liver and cardiovascular genetic diseases.
The plan aims for one-and-done therapies via DNA surgery over three years.
Led by Professor Zheng Zongli, the team uses engineered lipid nanoparticles (eLNPs) for delivery.
Drug candidates PL-100 and PL-200 target liver diseases and cardiovascular issues, emphasizing safety and efficacy.